An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Obinutuzumab (Primary) ; Chlorambucil
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Genentech
- 19 Sep 2016 Status changed from recruiting to completed.
- 27 Aug 2013 Actual initiation date changed form May 2013 to Aug 2013 as reported by ClinicalTrials.gov.
- 11 Jun 2013 New trial record